Selected Publications

Qian C, Worrede-Mahdi A, Shen F, DiNatale A, Kaur R, Zhang Q, Cristofanilli M, Meucci O, Fatatis A. Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy. Molecular Cancer Research. (2018).

Shahriari, K., Shen, F., Worrede-Mahdi A., Liu Q., Gong Y., Garcia F.U. and Fatatis A. Cooperation Among Heterogeneous Prostate Cancer Cells in the Bone Metastatic Niche. Oncogene 36, 2846-2858, (2017).

Shen, F.,  Zhang Y., Jernigan D.L., Yan J., Garcia F.U., Meucci O., Salvino J.M. and Fatatis A. Novel Small-molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Molecular Cancer Research 14, 518-527, 2016.

Liu Q., Russell MR., Shahriari K., Jernigan D., Lioni MI., Garcia FU and Fatatis A. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine feature. Cancer Research 73, 3297-3305, 2013.

Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O, and Fatatis A. The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Research 13, R91 2011.

Russell MR, Liu Q. and Fatatis A. Targeting the alpha receptor for Platelet-Derived Growth Factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clinical Cancer Research 16, 5002-5010 (2010). [Cover Article].

Russell M.R., Liu Q., Lei H., Kazlauskas A. and Fatatis A. The alpha receptor for Platelet   Derived Growth Factor confers bone-metastatic potential to prostate cancer cells by ligand and dimerization-independent mechanisms. Cancer Research 70, 4195-4203 (2010)

D’Ambrosio J and Fatatis A. Osteoblasts modulate Ca2+ signaling responses in bone-metastatic prostate and breast cancer cells. Clinical and Experimental Metastasis 26, 955-964 (2009).

Russell MR, Jamieson WL, Dolloff NG and Fatatis A. The a-Receptor for Platelet-Derived Growth Factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cellsOncogene 28, 412-412 (2009).

Jamieson W.L.. Shimizu S., D’Ambrosio J.A., Meucci, O. and Fatatis A. The CX3CR1 receptor is expressed by the prostate gland as its chemokine ligand fractalkine is detected in bone marrow and cleaved by an androgen-dependent mechanism: potential role in skeletal metastasis from prostate adenocarcinoma. Cancer Research 68, 1715-1722 (2008).

Dolloff N.G., Russell M.R., Loizos N. and Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha Platelet-derived Growth factor receptor. Cancer Research 67 555-562. (2007). Faculty of 1000-Biology – “Recommended Paper”

Dolloff N.G, Shulby S.S., Nelson A.V, Stearns M.E., Johannes G.J, Thomas J.D., Meucci O. and Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha Platelet Derived Growth Factor Receptor. Oncogene 24, 6848-6854, (2005).

Shulby, SA, Dolloff, NG, Stearns, ME, Meucci O. and Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration and survival of human prostate cancer cells. Cancer Research 64: 4693-4698 (2004).

Collaborative Studies

Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell (2018)

Ju X, Jiao X, Ertel A, Casimiro MC, Di Sante G, Deng S, Li Z, Di Rocco A, Zhan T, Hawkins, A, Stoyanova T, Andò S, Fatatis A, Lisanti MP, Gomella LG, Languino LR, Pestell RG. vSrc oncogene induces Trop2 proteolytic activation via cyclin D1. Cancer Research 76, 6723- 6734, (2016)

Wurth R., Tarn K., Jernigan D.L., Fernandez S.V., Cristofanilli M., Fatatis A., and Meucci O. A pre-clinical model of inflammatory breast cancer to study the involvement of CXCR4 and ACKr3 in the metastatic process. Translational Oncology 8, 358-367, (2015).

Gutierrez-Uzquiza A., Lopez-Haber C., Jernigan D.L., Fatatis A., and Kazanietz M.G. PKC epsilon is an essential mediator of prostate cancer bone metastasis. Molecular Cancer Research 13, 1336-1346, (2015)

Talati P.G.,  Gu L., Ellsworth E.M., Girondo M., Trerotola M., Hoang D.T., Leiby B., Dagvadorj A., McCue P.A., Lallas C.D., Trabulsi E.J., Gomella L., Aplin A., Languino, L. Fatatis A., Rui H., and Nevalainen M.T. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem Cell Properties in Prostate Cancer Cells. American J. Pathology 185, 2505-2522, (2015)

Sicoli d., Jiao X., Velasco-velazquez M., Ju X., Lisanti M., Ertel A., Addya S., Ando S., Fatatis A., Paudyal B., Thakur M. and Pestell R. CCR5 receptor antagonists block metastasis to bone of Src oncogene transformed metastatic prostate cancer cell lines. Cancer Research 74, 7103-7114, (2014)

Ferrari-Amorotti G., Chiodoni, C., Shen F., Cattelani S., Soliera A.R., Manzotti G., Grisendi G., Dominici M., Rivasi F.,  Colombo M.P., Fatatis A., and Calabretta B. Suppression of invasion and metastasis of triple negative breast cancer lines by pharmacological or genetic inhibition of Slug activity. Neoplasia 16, 1047-1058, (2014).

Caino M.C., Chae Y.C., Vaira V., Ferrero S., Nosotti M., Martin N.M., Weeraratna A., O’Connell M., Jernigan D.L., Fatatis A., Languino L.R., Bosari S., and Altieri D.C. Metabolic stress control of cytoskeletal dynamics and metastasis.  Journal of Clinical Investigation 123, 2907-2920, (2013).

Trerotola M., Jernigan D.L., Liu Q., Siddiqui J. Fatatis A. and Languino L.R. Trop-2 promotes cancer metastasis by modulating β1 integrin functions.  Cancer Research  73, 3155-3167, (2013)

Augello M.A., Burd C.J., Birbe R., McNair C., Ertel A., Magee M.S., Frigo D.E., Wilder-Romans K., Shilkrut M., Han S., Jernigan D.L., Dean J.L., Fatatis A., McDonnell D.P., Visakorpi T., Feng T.Y., and Knudsen K.E. Convergence of oncogenic and hormone receptor pathways promotes pro-metastatic phenotypes. Journal of Clinical Investigation 123, 493-508 (2013).